(1S)-1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethanol | 1041177-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: (1S)-1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethanol
• 英文别名: (1S)-1-(1-methylbenzimidazol-2-yl)ethanol
• CAS: 1041177-42-7
• 化学式: C₁₀H₁₂N₂O
• mdl: MFCD01050195
• 分子量: 176.218
• InChiKey: HXNWGBPRRHESCL-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(1-甲基-1H-苯并咪唑-2-基)乙酮 在 purple carrot 作用下， 以 乙醇 、 水 为溶剂， 以81 %的产率得到(1S)-1-(1-methyl-1H-benzo[d]imidazol-2-yl)ethanol
  参考文献：
  名称：

  医学相关氮杂芳酮的对映选择性生物还原

  摘要：

  我们在此报告了 FDA 批准的药物中最常用的含氮杂芳烃的酮的对映选择性生物还原。对这些含氮杂环的十个品种进行了系统研究。首次研究八类，七类耐受，显着扩大了植物介导还原的底物范围。通过在缓冲水介质中使用紫胡萝卜并采用简化的反应装置，这种生物催化转化在环境温度下在 48 小时内实现，为药物化学家提供了一种实用且可扩展的工具来获取各种含氮杂芳基的手性醇。凭借多个反应位点，结构多样的手性醇可用于库化合物制备、早期路线探索活动以及其他药物分子的合成，从而有利地加速药物化学活动。

  DOI：

  10.1021/acsmedchemlett.3c00114

文献信息

• RING-FUSED HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150284384A1

  公开（公告）日：2015-10-08

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R 1 represents optionally substituted lower alkyl and the like, R 2 represents optionally substituted lower alkyl and the like, R 3 represents the formula (II): (wherein, n represents 0 or 1, R 3a represents a hydrogen atom and the like, R 3b represents a hydrogen atom and the like, and R 3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W 1 represents a nitrogen atom and the like, W 2 represents a nitrogen atom and the like]

  根据本发明，环融合杂环化合物或其药学上可接受的盐具有T型钙通道调节作用，例如，可用作治疗和/或预防瘙痒的药物。本发明提供了由以下一般式(I)或其药学上可接受的盐等表示的环融合杂环化合物，具有T型钙通道调节作用，可用作治疗和/或预防瘙痒等疾病的治疗和/或预防剂。其中，R1代表可选取代的低碳基等，R2代表可选取代的低碳基等，R3代表公式(II)：（其中，n代表0或1，R3a代表氢原子等，R3b代表氢原子等，R3c代表氢原子等）等，Q代表氢原子等，W1代表氮原子等，W2代表氮原子等。
• CONDENSED RING HETEROCYCLIC COMPOUND
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2881394A1

  公开（公告）日：2015-06-10

  The ring-fused heterocyclic compound or a pharmaceutically acceptable salt thereof according to the present invention has a T-type calcium channel regulatory effect, and is useful, for example, as a medicament for treating and/or preventing pruritus. The present invention provides a ring-fused heterocyclic compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof and the like which has a T-type calcium channel regulatory effect and is useful as a therapeutic and/or preventive agent for pruritus, and the like. [wherein, R1 represents optionally substituted lower alkyl and the like, R2 represents optionally substituted lower alkyl and the like, R3 represents the formula (II): (wherein, n represents 0 or 1, R3a represents a hydrogen atom and the like, R3b represents a hydrogen atom and the like, and R3c represents a hydrogen atom and the like) and the like, Q represents a hydrogen atom and the like, and W1 represents a nitrogen atom and the like, W2 represents a nitrogen atom and the like]

  根据本发明的环融杂环化合物或其药学上可接受的盐具有 T 型钙通道调节作用，例如可用作治疗和/或预防瘙痒症的药物。本发明提供了由以下通式（I）代表的环融杂环化合物或其药学上可接受的盐等，该化合物具有 T 型钙通道调节作用，可用作治疗和/或预防瘙痒症等的药物。 [其中，R1 代表任选取代的低级烷基等，R2 代表任选取代的低级烷基等，R3 代表式 (II)： (其中，n 代表 0 或 1，R3a 代表氢原子等，R3b 代表氢原子等，R3c 代表氢原子等）等，Q 代表氢原子等，W1 代表氮原子等，W2 代表氮原子等]。
• Lipase mediated kinetic resolution of benzimidazolyl ethanols
  作者：Ravi Kumar Cheedrala、Rachna Sachwani、Palakodety Radha Krishna

  DOI：10.1016/j.tetasy.2008.03.021

  日期：2008.5

  Enantioselective trans-acylation of the racemic benzimidazolyl ethanols was achieved via enzymatic kinetic resolution. A range of commercially available lipases were screened and Novozyme-435 was established as the optimal catalyst. N-Protection was found to be mandatory for effective transesterification. However, electron-withdrawing substituents reduced the enantioselectivity to some extent when compared to the other substituents. (C) 2008 Published by Elsevier Ltd.
• US9540366B2
  申请人：——

  公开号：US9540366B2

  公开（公告）日：2017-01-10
• Enantioselective Bioreduction of Medicinally Relevant Nitrogen-Heteroaromatic Ketones
  作者：Wen-Ju Bai、Michelle A. Estrada、Jackson A. Gartman、Andrew S. Judd

  DOI：10.1021/acsmedchemlett.3c00114

  日期：2023.6.8

  scalable tool to access a broad variety of nitrogen-heteroaryl-containing chiral alcohols. With multiple reactive sites, the structurally diverse set of chiral alcohols can be used for library compound preparation, early route-scouting activities, and synthesis of other pharmaceutical molecules, favorably accelerating medicinal chemistry campaigns.

  我们在此报告了 FDA 批准的药物中最常用的含氮杂芳烃的酮的对映选择性生物还原。对这些含氮杂环的十个品种进行了系统研究。首次研究八类，七类耐受，显着扩大了植物介导还原的底物范围。通过在缓冲水介质中使用紫胡萝卜并采用简化的反应装置，这种生物催化转化在环境温度下在 48 小时内实现，为药物化学家提供了一种实用且可扩展的工具来获取各种含氮杂芳基的手性醇。凭借多个反应位点，结构多样的手性醇可用于库化合物制备、早期路线探索活动以及其他药物分子的合成，从而有利地加速药物化学活动。